SGS began recruiting participants in the U.S. in a multinational clinical trial of a potential drug candidate to treat COVID-19 related respiratory failure.
SGS was recently selected by French biotech company Biophytis to conduct its COVA study evaluating Sarconeos (BIO101) for the treatment of COVID-19 related respiratory failure.
The trial will recruit 310 participants for a maximum 28-day treatment in the Phase 2/3 trial, which will examine the drug’s safety, tolerability, and efficacy. All participants must have been tested positive for COVID-19, developed severe respiratory symptoms and show COVID-19 symptoms.
